Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The myeloproliferative disorders.

Campbell PJ, Green AR.

N Engl J Med. 2006 Dec 7;355(23):2452-66. Review. No abstract available.

PMID:
17151367
2.

JAK2: implications for diagnosis and classification of myeloproliferative disorders.

Campbell P.

Lijec Vjesn. 2007 May;129 Suppl 3:30-2. No abstract available.

PMID:
18959057
3.

The WHO 2008 classification of Ph-myeloproliferative disorders: statement of the Czech MPD Working Group.

Schwarz J, Penka M, Indrák K, Pospísilová D, Pytlík R, Dulícek P, Doubek M, Kren L, Campr V; Czech MPD Working Group..

Leukemia. 2008 Nov;22(11):2118-9. doi: 10.1038/leu.2008.93. Epub 2008 Apr 17. No abstract available.

PMID:
18418405
4.

The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.

Anastasi J.

Hematol Oncol Clin North Am. 2009 Aug;23(4):693-708. doi: 10.1016/j.hoc.2009.04.002. Review.

PMID:
19577165
5.

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].

Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.

Orv Hetil. 2006 Nov 12;147(45):2175-9. Hungarian.

PMID:
17402211
6.

[JAK2 mutation in myeloproliferative disorders].

Inokuchi K.

Rinsho Ketsueki. 2006 Aug;47(8):693-700. Review. Japanese. No abstract available.

PMID:
16986707
7.

Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.

Agarwal MB.

J Assoc Physicians India. 2007 Jul;55:507-10. Review.

PMID:
17907502
8.

[Molecular biology and new drug therapy for myeloproliferative neoplasm].

Kitanaka A, Shide K, Shimoda K.

Rinsho Ketsueki. 2013 Oct;54(10):1697-703. Review. Japanese. No abstract available.

PMID:
24064819
9.

Advances in the understanding and management of myeloproliferative disorders.

Skoda R.

Eur J Haematol Suppl. 2007 Oct;(68):2-4. Review. No abstract available.

PMID:
17727556
10.

JAK2 mutations and clinical practice in myeloproliferative neoplasms.

Tefferi A.

Cancer J. 2007 Nov-Dec;13(6):366-71. Review.

PMID:
18032973
11.

[The discovery of JAK2 mutation has changed the diagnostic criteria of myeloproliferative neoplasms].

Zhu P.

Zhonghua Yi Xue Za Zhi. 2008 Jul 1;88(25):1729-31. Chinese. No abstract available.

PMID:
19035079
12.

Genetic basis of MPN: Beyond JAK2-V617F.

Them NC, Kralovics R.

Curr Hematol Malig Rep. 2013 Dec;8(4):299-306. doi: 10.1007/s11899-013-0184-z. Review.

PMID:
24190690
13.

[Clinical aspects of myeloproliferative disorders excluding CML].

Komatsu N.

Rinsho Ketsueki. 2008 Oct;49(10):1411-9. Review. Japanese. No abstract available.

PMID:
18833926
14.

Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders.

Skoda R.

Eur J Haematol Suppl. 2007 Oct;(68):5-8. Review. No abstract available.

PMID:
17727557
15.

Molecular pathology of myeloproliferative neoplasms.

Klco JM, Vij R, Kreisel FH, Hassan A, Frater JL.

Am J Clin Pathol. 2010 Apr;133(4):602-15. doi: 10.1309/AJCPPPZ1WFVGNE4A. Review.

PMID:
20231614
16.

Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.

Panani AD.

Cancer Lett. 2009 Oct 18;284(1):7-14. doi: 10.1016/j.canlet.2009.02.010. Epub 2009 Mar 9. Review.

PMID:
19269737
17.

The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow.

Ingram W, Lea NC, Cervera J, Germing U, Fenaux P, Cassinat B, Kiladjian JJ, Varkonyi J, Antunovic P, Westwood NB, Arno MJ, Mohamedali A, Gaken J, Kontou T, Czepulkowski BH, Twine NA, Tamaska J, Csomer J, Benedek S, Gattermann N, Zipperer E, Giagounidis A, Garcia-Casado Z, Sanz G, Mufti GJ.

Leukemia. 2006 Jul;20(7):1319-21. Epub 2006 Apr 13. No abstract available.

PMID:
16617322
18.

An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era.

Zhang SJ, Li JY.

Chin Med J (Engl). 2008 Sep 20;121(18):1838-42. No abstract available.

PMID:
19080367
19.

Molecular classification of myeloproliferative neoplasms-pros and cons.

Qureshi M, Harrison C.

Curr Hematol Malig Rep. 2013 Dec;8(4):342-50. doi: 10.1007/s11899-013-0179-9. Review.

PMID:
24091831
20.

From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.

Cazzola M, Kralovics R.

Blood. 2014 Jun 12;123(24):3714-9. doi: 10.1182/blood-2014-03-530865. Epub 2014 Apr 30.

Supplemental Content

Support Center